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Progressive peritoneal fibrosis, membrane
hyperpermeability, and ultrafiltration failure have been
observed in patients on long-term peritoneal dialysis (PD).
The present study tested the hypothesis that reactive oxygen
species (ROS) generated by conventional PD solution (PDS)
mediate functional and structural alterations of peritoneal
membrane in vivo. Sprague–Dawley rats were randomized to
control, PDS, PDS with an antioxidant, and PDS with an
angiotensin II (Ang II) receptor blocker. Commercial PDS
containing 3.86% glucose (20–30 ml) with or without
N-acetylcystein (NAC) 10 mM or losartan 5 mg/kg was
administered intraperitoneally twice a day for 12 weeks.
Control rats received sham injection. Rats treated with PDS
had significantly lower drain volume and D4/D0 glucose, but
higher D4/P4 creatinine and increased membrane thickness
and endothelial NOS (eNOS) expression compared to control
rats. Omental transforming growth factor (TGF)-b1, vascular
endothelial growth factor (VEGF), collagen I, and heat-shock
protein (hsp) 47 expression and lipid peroxide levels and
dialysate VEGF and Ang II concentrations were significantly
increased in rats treated with PDS compared to control. All of
these changes were prevented by both NAC and losartan.
In conclusion, the present study demonstrates that ROS
generated by conventional PDS are, in large part, responsible
for peritoneal fibrosis and membrane hyperpermeability. We
suggest that antioxidants or Ang II receptor blockers may
allow better preservation of the structural and functional
integrity of the peritoneal membrane during long-term PD.
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Long-term peritoneal dialysis (PD) is associated with
progressive increase in the thickness of peritoneal membrane,
predominantly in the submesothelial compact collagenous
zone,1 and membrane hyperpermeability.2 The mechanisms
involved in these structural and functional changes remain
unclear, but prolonged exposure of the membrane to conven-
tional PD solution (PDS) containing high concentrations
of glucose and glucose degradation products (GDP) may
play an important role. We have previously demonstrated
that conventional high glucose-containing PDS increases
transforming growth factor-b1 (TGF-b1), vascular endo-
thelial growth factor (VEGF), and procollagen III N-terminal
peptide secretion by human peritoneal mesothelial cells
(HPMC),3 and that high glucose-induced activation of
protein kinase C mediates TGF-b1 and fibronectin upregula-
tion in HPMC.4 We also showed that conventional PDS5 and
high glucose6 increase cellular reactive oxygen species (ROS)
in HPMC, that high glucose-induced ROS generation is
dependent on activation of protein kinase C, nicotinamide
adenine dinucleotide phosphate oxidase, and mitochondrial
metabolism, and that ROS provide signal amplification in
high glucose-induced fibronectin expression by HPMC.6
Recently, we demonstrated that high glucose increases cellu-
lar and secreted angiotensin II (Ang II) in HPMC, that Ang II
induces TGF-b1 and fibronectin upregulation through gene-
ration of cellular ROS, and that losartan and captopril signi-
ficantly reduce high glucose-induced TGF-b1 and fibronectin
secretion by HPMC.7
Mortier et al.8,9 demonstrated that chronic exposure of rat
peritoneum to conventional PDS containing high concentra-
tions of glucose and GDP resulted in loss of ultrafiltration
capacity, increased vascular density, development of fibrosis,
and higher accumulation of advanced glycation end-products
but not when exposed to new solution containing low
concentration of GDP, suggesting that GDP may play a role
in the PDS-induced peritoneal changes. GDP can generate
intracellular ROS and signal through ROS. Methylglyoxal-
induced heparin-binding epidermal growth factor-like
growth factor mRNA expression in rat aortic smooth muscle
cells10 and methylglyoxal-induced VEGF secretion by HPMC
(HB Lee et al., unpublished data) were shown to be suppres-
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sed by antioxidant N-acetylcystein (NAC). Acetaldehyde-
induced a1(I) procollagen gene expression in mouse hepatic
stellate cells was also blocked by catalase.11 GDP are pre-
cursors of advanced glycation end-products, which also
induce cellular ROS by direct action12 and through binding
their receptor for advanced glycation end-products13 and
signal through ROS.14 ROS, in turn, promote advanced
glycation end-products formation15 and can thereby amplify
advanced glycation end-products signal.
In this study, we tested our hypothesis that ROS generated
by conventional PDS, regardless of whether they are from
high glucose, GDP, or Ang II, may play a role in peritoneal
membrane alterations in vivo and that antioxidant may
prevent such changes. We specifically examined the effect of
Ang II type 1 receptor blocker in PDS-induced membrane
alterations in view of the fact that Ang II generates and
signals through ROS in HPMC.7
RESULTS
Peritoneal permeability and drained volume
At the end of 12 weeks, rats treated with PDS had signi-
ficantly lower drain volume and D4/D0 glucose, but higher
D4/P4 creatinine compared to control rats. Both NAC and
losartan prevented the decrease in drain volume and D4/D0
glucose and the increase in D4/P4 creatinine (Figure 1).
Peritoneal membrane thickness
Subhepatic peritoneal membrane showed intact mesothelial
cell monolayer in control rats (Figure 2a). In rats treated with
PDS, a significant increase in peritoneal thickness with collagen
deposition in submesothelial layer was observed (Figure 2a).
Both NAC and losartan prevented the increase in thickness
of both visceral and parietal peritoneum (Figure 2a and b).
Expression of eNOS
In control rats, a faint signal for endothelial NOS (eNOS) was
located in the endothelial lining. In rats treated with PDS,
there was an intense eNOS signal along the vessel wall.
Both NAC and losartan attenuated the increase in the signal
(Figure 3).
Omental collagen I and hsp 47 expression
Omental collagen I and heat-shock protein (hsp) 47
expression was significantly increased in rats treated with
PDS compared to control rats. Both NAC and losartan
prevented the increase (Figure 4).
Omental TGF-b1, VEGF, and LPO
Omental TGF-b1 (Figure 5a) and VEGF (Figure 5b)
expression was significantly increased in rats treated with
PDS compared to control. Both NAC and losartan signi-
ficantly inhibited PDS-induced increase in TGF-b1 and VEGF.
Omental lipid peroxide (LPO) (Figure 5c) also increased in
rats treated with PDS, although the difference did not reach
statistical significance. Losartan significantly reduced LPO in
omentum when compared to rats treated with PDS without
NAC or losartan.
Dialysate TGF-b1, VEGF, and Ang II
Dialysate TGF-b1 also increased in rats treated with PDS and
the treatment with both NAC and losartan attenuated the
increase, although the changes did not reach statistical
significance (Figure 6a). Dialysate VEGF (Figure 6b) and Ang
II (Figure 6c) concentrations significantly increased in rats
treated with PDS compared to control and both NAC and
losartan significantly inhibited PDS-induced increase in
VEGF and Ang II.
DISCUSSION
In this study, we hypothesized that cellular ROS generated by
conventional PDS may play a role in structural and
functional peritoneal changes observed during long-term
PD and that antioxidant may prevent such changes.
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Figure 1 | Effect of PDS with or without NAC or losartan on peritoneal permeability and ultrafiltration capacity. Peritoneal equilibration
test using 4.25% glucose PDS was performed immediately before being killed. Values are mean7s.e. of seven to eight animals. *Po0.05 versus
control; wPo0.05 versus PDS-treated rats.
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Figure 2 | Effect of NAC or losartan on PDS-induced peritoneal membrane thickening. (a) Masson’s trichrome staining of subhepatic
peritoneal membrane was performed as described in Materials and Methods. Original magnification,  400. (b) Maximal peritoneal membrane
thickness was measured by Image Pro Plus as described in Materials and Methods. Values are mean7s.e. of seven to eight animals. *Po0.05
versus control; wPo0.05 versus PDS-treated rats.
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Figure 3 | Effect of NAC and losartan on PDS-induced expression
of eNOS. Immunohistochemical staining for eNOS in the parietal
peritoneal membrane was performed as described in Materials and
Methods. Original magnification,  400.
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Figure 4 | Effect of NAC or losartan on PDS-induced expression of
collagen I and hsp 47. Protein was extracted from omental tissue
and was subjected to Western blot analysis. Left panel shows a
representative Western blot, and right panel represents relative
increase as mean7s.e. of seven to eight animals. Equal amount of
samples were verified by Ponceau S staining. *Po0.05 versus control.
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In our animal model of PD where the peritoneum was
exposed to PDS over 12 weeks, we observed changes similar
to those observed in long-term PD patients with increased
transport of creatinine and glucose, decreased ultrafiltration
capacity, and increased peritoneal thickening and new vessel
formation. In rats treated with PDS, thickening of peritoneal
membrane was observed in both parietal and visceral peri-
toneum and this was associated with increased omental
collagen I and hsp 47 expression. Hsp 47 is a collagen-specific
molecular chaperon during the synthesis and/or secretion of
procollagen.16 In various renal diseases including renal inters-
titial fibrosis induced by unilateral ureteral obstruction,17
experimental mesangioproliferative glomerulonephritis,18
and age-related nephropathy,19 the expression of hsp 47
was shown to be correlated with the degree of collagen
expression. Recently, Mishima et al.20 showed marked
increase in hsp 47 expression in mesothelial cells and in sub-
mesothelial connective tissue in chlorhexidine gluconate-
induced peritoneal fibrosis. These observations together with
our finding in this study suggest that hsp 47 is a good marker
of collagen accumulation in the kidney and peritoneum.
Our finding that antioxidant NAC prevented PDS-induced
collagen I and hsp 47 accumulation in the omentum strongly
suggests that ROS are the major mediator of peritoneal
fibrosis.
TGF-b1 is a multifunctional cytokine that is central in
the process of fibrogenesis.21 It is generally accepted that
TGF-b1 is locally produced in the peritoneum3 and is likely
to be the main growth factor for functional and structural
changes of peritoneal membrane.22,23 TGF-b1 gene transfer
to rat peritoneum was shown to induce peritoneal fibrosis,
neoangiogenesis, increase of peritoneal solute transport,22
and epithelial–mesenchymal transition.23 Our observations
that omental and dialysate TGF-b1 increased in rats treated
with PDS, that the expression of TGF-b1 coincided with
functional and structural changes in peritoneal membrane,
and that the increase in TGF-b1 was effectively prevented by
NAC strongly suggest the involvement of ROS in peritoneal
alterations.
VEGF is a mitogen for endothelial cells and a regulator of
normal and abnormal angiogenesis24 and induces vascular
hyperpermeability by a direct action on endothelial cells.25
VEGF is locally produced in the peritoneum,3,26,27 has been
identified in biopsy samples from long-term PD patients,26
and dialysate VEGF was shown to correlate with solute
transport.27 eNOS also plays a role in the control of vascular
tone and permeability28,29 as well as angiogenesis via an
interaction with VEGF.30,31 Functional significance of eNOS
in the peritoneal membrane permeability has been reported
in acute peritonitis mouse model.32 In this study, PDS-
induced increase in omental and dialysate VEGF and peri-
toneal eNOS expression was significantly prevented by NAC,
again suggesting the involvement of ROS in functional as well
as structural changes in the peritoneum.
Ang II is a growth factor that regulates cell proliferation,
apoptosis, and fibrosis.33–35 Recently, we demonstrated that
high glucose increases cellular and secreted Ang II in cultured
HPMC, that Ang II generates cellular ROS, and that Ang II-
induced upregulation of TGF-b1 and fibronectin was inhi-
bited by catalase and diphenyleneiodinium, an nicotinamide
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Figure 5 | Effect of NAC or losartan on (a) PDS-induced omental
TGF-b1, (b) VEGF, and (c) LPO levels. Omental TGF-b1 and VEGF
content was measured by ELISA and LPO by modified thiobarbituric
acid method as described in Materials and Methods. Values are
mean7s.e. of six to eight animals. *Po0.05 versus control;
wPo0.05 versus PDS-treated rats.
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Figure 6 | Effect of PDS with or without NAC or losartan on (a)
dialysis effluent concentrations of TGF-b1, (b) VEGF, and (c) Ang
II. TGF-b1, VEGF, and Ang II concentrations were measured by ELISA
as described in Materials and Methods. Values are mean7s.e. of five
to eight animals. *Po0.05 versus control; wPo0.05 versus PDS-treated
rats.
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adenine dinucleotide phosphate oxidase inhibitor, in
HPMC.7 These observations suggested that the effect of
Ang II on peritoneal changes is mediated by ROS. Our
current observation that losartan effectively lowers omental
LPO level and, at the same time, prevents peritoneal hyper-
permeability, eNOS expression, and membrane thickening
confirms that the effect of Ang II on peritoneal changes is
mediated by ROS. The involvement of nicotinamide adenine
dinucleotide phosphate oxidase in Ang II-induced ROS
generation has also been identified in vascular smooth muscle
cells36 and endothelial cells.37 A study by Hsieh et al.38 showed
that high glucose enhances angiotensinogen gene expression
via ROS generation in rat kidney proximal tubular cells.
Interestingly, we found that NAC decreases dialysate Ang
II. This suggests that ROS are not only downstream but
also upstream signaling molecules to Ang II in PDS-induced
peritoneal injury. We also observed that the increase in
dialysate Ang II induced by PDS was prevented by losartan,
suggesting a positive feedback system by which the
internalized Ang II is responsible for enhanced generation
of Ang II. Such a link between Ang II receptor activation and
stimulation of local Ang II formation is in agreement with
previous studies,39–41 which showed that Ang II type 1 recep-
tor stimulation augments intrarenal Ang II in Ang II-induced
hypertension. The beneficial effect of losartan in the present
study is consistent with an earlier study showing that
intraperitoneal enalapril improves ultrafiltration capacity
and decreases peritoneal thickening.42
GDP can induce intracellular ROS and signal through
ROS10,11 and are likely to contribute to conventional PDS-
induced peritoneal alterations. We, however, did not use a
control GDP-depleted PDS in this study because we found
that GDP-depleted PDS generated almost as much ROS
in HPMC as PDS containing high concentration of GDP
(data not shown) probably from high glucose.
In conclusion, the present study strongly suggests that
ROS generated by conventional PDS, regardless of whether
produced by high glucose, Ang II, or GDP, may be respon-
sible for progressive membrane hyperpermeability, neo-
angiogenesis, accumulation of extracellular matrix, and
eventual peritoneal fibrosis. Thus, antioxidants or Ang II
receptor blockers may allow better preservation of the struc-
tural and functional integrity of the peritoneal membrane
during long-term PD.
MATERIALS AND METHODS
All chemicals and materials, unless otherwise stated, were obtained
from Sigma Chemical Company (St Louis, MO, USA) and Becton
Dickinson Labware (Lincoln Park, NJ, USA).
Animals and treatment
Male Sprague–Dawley rats weighing 250 g were purchased from Bio
Genomics Inc. (Seoul, Korea) and housed in a room under
controlled temperature (23711C) and humidity (45–65%), 12-h
light/dark cycle, and free access to water and chow (Samyang rat
food, Seoul, Korea). All animal experiments were conducted in
accordance with the National Institute of Health guide for the care
and use of laboratory animals. Rats were randomized to four groups
(n¼ 8 for each group): control, PDS, PDS with an antioxidant, and
PDS with an Ang II receptor blocker. Commercial PDS containing
3.86% glucose, 20–30 ml depending upon the body weight change
over time, with or without NAC 10 mM or losartan 5 mg/kg was
administered intraperitoneally twice a day for 12 weeks. Dose of NAC
was chosen based on the previous study43 and our own preliminary
data using 5, 10, and 50 mM and that of losartan based on the
previous study.44 pH of PDS was neutralized by NaOH and the final
pH was 7.4. Control rats received sham injection (puncture of the
peritoneal cavity without PDS) twice a day over 12 weeks. Peritoneal
equilibration test was performed over 4 h before being killed. Rats
were killed using pentobarbital sodium, blood and dialysate samples
were collected, and omental tissue, liver, and anterior abdominal wall
apart from injection site were removed and frozen until analysis.
There was no evidence of infection at the puncture site or in the
peritoneal cavity from repeated punctures. One animal each from
control and losartan groups died during the study period.
Peritoneal equilibration test
Peritoneal equilibration test was performed using 30 ml of 3.86%
glucose PDS. Four hours later, a tail blood sample and a dialysate
sample were obtained. The dialysate to plasma creatinine ratio at
4 h (D4/P4 creatinine) was used as the solute transport parameter.
The drained volume was calculated as the sum of peritoneal fluid
aspirated and the weight of (wet-dry) gauze at 4 h. The creatinine
concentration in the PD effluent was measured by modified Jaffe
method and corrected for glucose interference by a correction factor
derived by our laboratory.
Enzyme-linked immunosorbent assay
Total TGF-b1 (after acid activation) and VEGF were measured in
dialysate and omental tissue using a commercial sandwich enzyme-
linked immunosorbent assay (ELISA) kit for TGF-b1 (R&D Systems,
Minneapolis, MN, USA) and VEGF (R&D systems) according to
the manufacturer’s descriptions. Omental tissue was homogenized
in a standard lysis buffer containing protease inhibitors (20 mM Tris-
HCl, 1% Triton X-100, 137 mM sodium chloride, 5 mM ethylene-
diaminetetraaceticacid, 1 mM ethyleneglycol tetraacetate, 0.2 mM
phenylmethylsulfonylfluoride, 10 mM leupeptin, 1 mg/ml aprotinin).
Ang II was measured in dialysate using a commercial ELISA kit
(Peninsula Laboratories, Belmont, CA, USA). Before the detection
of Ang II, 1 ml of dialysate samples were lyophilized and
reconstituted in 60ml of H2O.
Western blot analysis
Protein was extracted from frozen omental tissue by homogeniza-
tion in a lysis buffer with the same composition as was used for
ELISA. After electrophoresis, the proteins were transferred onto a
nitrocellulose membrane using a transblot chamber with Tris buffer
(0.025 M Tris-HCl, 0.192 M glycine, and 20% MeOH). Equal amount
of samples were verified by Ponceau S staining. The membrane
was blocked for 1 h at room temperature with 5% non-fat milk in
Tris-buffered saline-Tween 20. Membranes were incubated at 41C
overnight with rat monoclonal antibody to collagen I (Southern
Biotech, Birmingham, AL) or hsp 47 (Stressgen, Victoria, BC,
Canada). After extensive washing in Tris-buffered saline-Tween 20,
the membranes then were incubated with horseradish peroxidase-
conjugated anti-mouse immunoglobulin G or anti-goat immuno-
globulin G for 1 h at room temperature. After washing, the
membranes were incubated with enhanced chemiluminescence
2026 Kidney International (2006) 69, 2022–2028
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system detection kit (Amersham Life Science, Little Chalfont, UK).
Positive immunoreactive bands were quantified densitometrically.
Lipid peroxidation
The omental tissue samples were homogenized in a buffer solution
containing 50 mM Tris-HCl (pH 7.4) and 1.15% KCl, and then
centrifuged. The supernatant was used for the assay. The levels of
lipid peroxidation were measured by thiobarbituric acid method
with a modification as described previously.45
Histological assessment
Tissue samples obtained from the liver and anterior abdominal wall
were fixed in a sufficient amount of 4% phosphate-buffered
formaldehyde for 24 h, paraffin-processed and embedded, and
3 mm sections were cut. Cut sections were stained with Masson’s
trichrome stain. In histological assessment, attention was paid to the
morphologic features of the mesothelial surface and submesothelial
compact zone. The integrity of the mesothelial cell monolayer was
assessed and the maximal thickness of the submesothelial compact
zone was measured in subhepatic and parietal peritoneal membrane
using Image Pro Plus (Media Cybernetics, Silver Spring, MD, USA).
Four-micrometer paraffin sections were processed for immuno-
histochemistry using avidin–biotin–horseradish peroxidase tech-
nique, as described previously.46,47 The sections were deparaffined
with xylene and ethanol, rinsed in tap water, and incubated with
3% H2O2 for 30 min to eliminate endogenous peroxidase activity.
Before incubation with primary antibody, the sections were
permeabilized by incubation for 15 min in 0.5% Triton X-100 in
phosphate-buffered saline, blocked subsequently with blocking
serum for 30 min, and incubated overnight at 41C with the antibody
against eNOS (1:1000; Transduction Lab., Lexington, KY, USA)
diluted in phosphate-buffered saline. After washing in phosphate-
buffered saline, the sections were incubated for 2 h with the
biotinylated secondary antibody against mouse immunoglobulin G,
and subsequently with the Vectastain ABC reagent (Vectastain ABC
kit; Vector Laboratories, Burlington, CA, USA) for 2 h. After rinsing
with phosphate-buffered saline, the sections were incubated with the
peroxidase substrate solution, a mixture of 0.05% 3,30-diamino-
benzidine, and 0.01% H2O2 for 2 min at room temperature. After
rinsing with Tris-HCl buffer, the sections were dehydrated with
graded ethanol and xylene, mounted in Canada balsam, and
examined by light microscope.
Statistical analyses
The mean values obtained from each group were compared by
analysis of variance with subsequent Fisher’s significant difference
method. Non-parametric analyses were also used where appropriate.
A P-value o0.05 was used as the criterion for a statistically
significant difference.
ACKNOWLEDGMENTS
This work was supported by a grant from Department of Health and
Welfare, Republic of Korea (Grant No. 02-PJ1-PG3-21499-0005).
REFERENCES
1. Williams JD, Craig KJ, Topley N, et al., Peritoneal Biopsy Study Group.
Morphologic changes in the peritoneal membrane of patients with renal
disease. J Am Soc Nephrol 2002; 13: 470–479.
2. Davies SJ, Phillips L, Naish PF, Russell GI. Peritoneal glucose exposure and
changes in membrane solute transport with time on peritoneal dialysis.
J Am Soc Nephrol 2001; 12: 1046–1051.
3. Ha H, Cha MK, Choi HN, Lee HB. Effects of peritoneal dialysis solutions
on the secretion of growth factors and extracellular matrix proteins
by human peritoneal mesothelial cells. Periton Dial Int 2002; 22:
171–177.
4. Ha H, Yu MR, Lee HB. High glucose-induced PKC activation mediates
TGF-beta 1 and fibronectin synthesis by peritoneal mesothelial cells.
Kidney Int 2001; 59: 463–470.
5. Ha H, Song JS, Yu MR, Lee HB. Oxidative stress in peritoneal dialysis.
Lect Notes ICB Semin 2004; 65: 32–39.
6. Lee HB, Yu MR, Song JS, Ha H. Reactive oxygen species amplify protein
kinase C signaling in high glucose-induced fibronectin expression by
peritoneal mesothelial cells. Kidney Int 2004; 65: 1170–1179.
7. Noh H, Ha H, Yu MR et al. Angiotensin II mediates high glucose-induced
TGF-b1 and fibronectin upregulation in HPMC through reactive oxygen
species. Periton Dial Int 2005; 25: 38–47.
8. Mortier S, Faict D, Schalkwijk CG et al. Long-term exposure to new
peritoneal solutions: effects on the peritoneal membrane. Kidney Int 2004;
66: 1257–1265.
9. Mortier S, Faict D, Lameire NH, De Vriese AS. Benefits of switching from a
conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution
in a rat model. Kidney Int 2005; 67: 1559–1565.
10. Che W, Asahi M, Takahashi M et al. Selective induction of heparin-binding
epidermal growth factor-like growth factor by methyllglyoxal and
3-deoxyglucosone in rat aortic smooth muscle cells. J Biol Chem 1997;
272: 18453–18459.
11. Greenwel P, Dominguez-Rosales JA, Mavi G et al. Hydrogen peroxide: a
link between acetaldehyde-elicited alpha1(I) collagen gene up-regulation
and oxidative stress in mouse hepatic stellate cells. Hepatology 2000; 31:
109–116.
12. Yim MB, Yim HS, Lee C et al. Protein glycation: creation of catalytic sites
for free radical generation. Ann NY Acad Sci 2001; 928: 48–53.
13. Wautier MP, Chappey O, Corda S et al. Activation of NADPH oxidase by
AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol
2001; 280: E685–E694.
14. Lal MA, Brismar H, Eklof AC, Aperia A. Role of oxidative stress in advanced
glycation end product-induced mesangial cell activation. Kidney Int 2002;
61: 2006–2014.
15. Nishigawa T, Edelstein D, Du XL et al. Normalizing mitochondrial
superoxide production blocks three pathways of hyperglycaemic
damage. Nature 2000; 404: 787–790.
16. Nakai A, Satoh M, Hirayoshi K, Nagata K. Involvement of the stress protein
HSP 47 in procollagen processing in the endoplasmic reticulum. J Cell Biol
1992; 117: 903–914.
17. Moriyama T, Kawada N, Ando A et al. Up-regulation of HSP 47 in the
mouse kidneys with unilateral ureteral obstruction. Kidney Int 1998; 54:
110–119.
18. Razzaque MS, Taguchi T. Collagen-binding heat shock protein (HSP) 47
expression in anti-thymocyte serum (ATS)-induced glomerulonephritis.
J Pathol 1997; 183: 24–29.
19. Razzaque MS, Shimokawa I, Nazneen A et al. Age-related nephropathy in
the Fischer 344 rat is associated with overexpression of collagens and
collagen-binding heat shock protein 47. Cell Tissue Res 1998; 294:
471–578.
20. Mishima Y, Miyazaki M, Abe K et al. Enhanced expression of heat shock
protein 47 in rat model of peritoneal fibrosis. Periton Dial Int 2003; 23:
14–22.
21. Border WA, Noble NA. Transforming growth factor b in tissue fibrosis.
N Engl J Med 1994; 331: 1286–1292.
22. Margetts PJ, Kolb M, Galt T et al. Gene transfer of transforming growth
factor-b1 to the rat peritoneum: effects on membrane function. J Am Soc
Nephrol 2001; 12: 2029–2039.
23. Margetts PJ, Bonniaud P, Liu L et al. Transient overexpression of TGF-b1
induces epithelial mesenchymal transition in the rodent peritoneum.
J Am Soc Nephrol 2005; 16: 425–436.
24. Ferrara N. Role of vascular endothelial growth factor in the regulation of
angiogenesis. Kidney Int 1999; 56: 794–814.
25. Hippenstiel S, Kru¨ll M, Ikemann A et al. VEGF induces hyperpermeability
by a direct action on endothelial cells. Am J Physiol 1998; 274:
L678–L684.
26. Combet S, Miyata T, Moulin P et al. Vascular proliferation and enhanced
expression of endothelial nitric oxide synthase in human peritoneum
exposed to long term peritoneal dialysis. J Am Soc Nephrol 2000; 11:
717–728.
27. Zweers MM, Struijk DG, Smit W, Krediet RT. Vascular endothelial growth
factor in peritoneal dialysis: a longitudinal follow-up. J Lab Clin Med 2001;
137: 125–132.
28. Kubes P. Nitric oxide affects microvascular permeability in the intact and
inflamed vasculature. Microcirculation 1995; 2: 235–244.
Kidney International (2006) 69, 2022–2028 2027
H Noh et al.: ROS and peritoneal injury o r i g i n a l a r t i c l e
29. Kone BC. Nitric oxide in renal health and disease. Am J Kidney Dis 1997;
30: 311–333.
30. Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC. Nitric oxide
production contributes to the angiogenic properties of vascular
endothelial growth factor in human endothelial cells. J Clin Invest 1997;
100: 3131–3139.
31. Murohara T, Asahara T, Silver M et al. Nitric oxide synthase modulates
angiogenesis in response to tissue ischemia. J Clin Invest 1998; 101:
2567–2578.
32. Ni J, Moulin P, Gianello P et al. Mice that lack endothelial nitric
oxide synthase are protected against functional and structural
modifications induced by acute peritonitis. J Am Soc Nephrol 2003; 14:
3205–3216.
33. Ruiz-Ortega M, Lorenzo O, Suzuki Y et al. Proinflammatory actions
of angiotensins. Curr Opin Nephrol Hypertens 2001; 10: 321–329.
34. Wolf G, Neilson EG. Angiotensin II as a renal growth factor. J Am Soc
Nephrol 1993; 3: 1531–1540.
35. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis.
Hypertension 2001; 38: 635–638.
36. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in
cardiovascular biology and disease. Circ Res 2000; 86: 494–501.
37. Li JM, Shah AM. Mechanism of endothelial cell NADPH oxidase activation
by angiotensin II. J Biol Chem 2003; 278: 12094–12100.
38. Hsieh TJ, Zhang SL, Filep JG et al. High glucose stimulates
angiotensinogen gene expression via reactive oxygen species in rat
kidney proximal tubular cells. Endocrinology 2002; 143: 2975–2985.
39. Zou LX, Imig ZD, Von Thun AM et al. Receptor-mediated intrarenal
angiotensin II augmentation in angiotensin II-infused rats. Hypertension
1996; 28: 669–677.
40. Nishiyama A, Seth DM, Naver LG. Angiotensin II type 1 receptor-mediated
augmentation of renal interstitial fluid angiotensin II in angiotensin
II-induced hypertension. J Hypertens 2003; 21: 1897–1903.
41. Kobori H, Prieto-Carrasquero MC, Ozawa Y, Naver LG. AT1 receptor
mediated augmentation of intrarenal angiotensinogen in angiotensin
II-dependent hypertension. Hypertension 2004; 43: 1126–1132.
42. Duman S, Wieczorowska-Tobis K, Styszynski A et al. Intraperitoneal
enalapril ameliorates morphologic changes induced by hypertonic
peritoneal dialysis solutions in rat peritoneum. Adv Periton Dial 2004; 20:
31–36.
43. Pat B, Yang T, Kong C et al. Activation of ERK in renal fibrosis after
unilateral obstruction: modulation by antioxidants. Kidney Int 2005; 67:
931–943.
44. Ferrario CM, Jessup J, Chappell MC et al. Effect of angiotensin converting
enzyme inhibition and angiotensin II receptor blockers on cardiac
angiotensin converting enzyme 2. Circulation 2005; 111: 2605–2610.
45. Ha H, Yu MR, Kim KH. Melatonin and taurine reduce early glomerulopathy
in diabetic rats. Free Radic Biol Med 1999; 26: 944–950.
46. Han KH, Jung JY, Cha JH et al. 1,25-Dihydroxyvitamin D3 stimulates
osteopontin expression in rat kidney. Nephron Physiol 2003; 93: 76–86.
47. Han KH, Lim JM, Kim WY et al. Expression of endothelial nitric oxide
synthase in developing rat kidney. Am J Physiol Renal Physiol 2005; 288:
F694–F702.
2028 Kidney International (2006) 69, 2022–2028
o r i g i n a l a r t i c l e H Noh et al.: ROS and peritoneal injury
